Loading
An oral SERD is a pill that destroys the oestrogen receptor rather than just blocking it, replacing the monthly fulvestrant injection.
Selective oestrogen receptor degraders taken orally: elacestrant (2023), imlunestrant (2025), camizestrant (2026), giredestrant (filed), with palazestrant and others behind. Benefit as monotherapy is confined to ESR1-mutant disease; combination with CDK4/6 or everolimus extends benefit to wild-type tumours (EMBER-3, evERA). Upfront replacement of aromatase inhibitors in unselected first-line disease failed in persevERA. Adjuvant results (lidERA) are positive.
In plain words · The hormone switch that drives most breast cancers. Blocking or destroying it is the oldest and most effective targeted therapy.
Showing the target this term concerns: Estrogen receptor (ERα).
Shares Imlunestrant, Giredestrant, Camizestrant, Elacestrant.
Shares EMBER-3, Imlunestrant, Camizestrant, HR-positive / HER2-negative breast cancer.
Shares Imlunestrant, Camizestrant, Elacestrant, Estrogen receptor (ERα).
Shares Elacestrant, Estrogen receptor (ERα), Fulvestrant, HR-positive / HER2-negative breast cancer.
Shares EMBER-3, Imlunestrant, Camizestrant, Elacestrant.
Shares Giredestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Camizestrant, Fulvestrant, HR-positive / HER2-negative breast cancer.
Shares Giredestrant, Fulvestrant, HR-positive / HER2-negative breast cancer.